Share on StockTwits

BTG plc (LON:BTG)‘s stock had its “sell” rating reaffirmed by equities research analysts at Nplus1 Brewin in a research note issued to investors on Tuesday. They currently have a GBX 486 ($8.18) price target on the stock. Nplus1 Brewin’s price objective points to a potential downside of 16.49% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of BTG plc in a research note on Friday. They now have a GBX 655 ($11.03) price target on the stock. Separately, analysts at N+1 Singer cut their price target on shares of BTG plc from GBX 488 ($8.21) to GBX 486 ($8.18) in a research note on Thursday, May 22nd. They now have a “sell” rating on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of BTG plc in a research note on Tuesday, May 20th. They now have a GBX 525 ($8.84) price target on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of GBX 571.88 ($9.63).

BTG plc (LON:BTG) traded up 1.55% during mid-day trading on Tuesday, hitting GBX 591.00. The stock had a trading volume of 630,881 shares. BTG plc has a one year low of GBX 351.20 and a one year high of GBX 624.00. The stock’s 50-day moving average is GBX 540.1 and its 200-day moving average is GBX 557.7.

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.